Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 302.00K | 973.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 302.00K | 973.00K |
| Cost of Revenue | 450.00K | 46.87M | 12.43M | 6.66M | 227.00K |
| Gross Profit | -450.00K | -46.87M | -12.43M | -6.36M | 746.00K |
| SG&A Expenses | 6.18M | 7.31M | 4.97M | 4.75M | 3.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.51M | -- | -- | -- | -- |
| Total Operating Expenses | 25.27M | 54.18M | 17.39M | 11.40M | 9.52M |
| Operating Income | -25.27M | -54.18M | -17.39M | -11.10M | -8.54M |
| Income Before Tax | -23.48M | -52.37M | -15.54M | -94.21M | -8.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.48M | -52.37M | -15.54M | -94.21M | -8.18M |
| Earnings from Discontinued Operations | -- | 62.00K | -450.00K | 3.00M | -2.15M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.48M | -52.31M | -15.99M | -91.21M | -10.33M |
| EBIT | -25.27M | -54.18M | -17.39M | -11.10M | -8.54M |
| EBITDA | -25.23M | -54.14M | -17.35M | -11.06M | -8.51M |
| EPS Basic | -1.66 | -5.38 | -2.45 | -19.99 | -2.28 |
| Normalized Basic EPS | -1.04 | -3.36 | -1.49 | -1.28 | -1.13 |
| EPS Diluted | -1.66 | -5.38 | -2.45 | -19.99 | -2.28 |
| Normalized Diluted EPS | -1.04 | -3.36 | -1.49 | -1.28 | -1.13 |
| Average Basic Shares Outstanding | 14.18M | 9.73M | 6.53M | 4.56M | 4.54M |
| Average Diluted Shares Outstanding | 14.18M | 9.73M | 6.53M | 4.56M | 4.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |